Novo Nordisk (NVO) dropped 1.9% to $48.25 and trades more than 50% below its 52-week high.
Novo Nordisk earnings collapsed 26.5% year-over-year despite operating in the obesity treatment market.
Competitive pressure from Eli Lilly (LLY) has intensified as Zepbound gains market share rapidly.
If you’re thinking about retiring or know someone who is, there are three quick questions causing many Americans to realize they can retire earlier than expected. take 5 minutes to learn more here
Shares of Novo Nordisk A/S (NYSE: NVO) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of $45.05. Sometimes we see a divergence in share price and sentiment, but with Novo Nordisk they’re actually well correlated.
Discussion on Reddit has remained uniformly bearish throughout November. Novo Nordisk is trading more than 50% below its 52-week high, a stunning collapse for a company that was once viewed as the premier play on the obesity treatment revolution.
While not the only reason, it’s easy to see a notable downward trend in Google Trends for both of Novo Nordisk’s premier GLP-1 products, Ozempic and Wegovy
Despite strong underlying fundamentals like a 71.5% return on equity and huge 32.9% net income margin, retail traders are persistently skeptical about the Danish drugmaker’s future.
Activity on r/WallStreetBets has been consistently negative. Sentiment scores have ranged from a low of 18, to only as high as 30 this moth. When 50/100 considered perfectly neutral, this is deep in bearish territory. The most active period occurred on November 10, when one poster asked “where’s the n bottom?”
Novo Nordisk down another 2% today, where’s the bottom?
by
u/BearishOnPharma in
wallstreetbets
Retail investors are focusing on fundamental deterioration with Novo Nordisk’s position as a leader in GLP-1 treatments. The concerns are rooted in:
Earnings collapsed 26.5% year-over-year despite operating in the supposedly booming obesity treatment market
Revenue growth slowed to just 5.1% YoY, a steep deceleration
Competitive pressure from Eli Lilly (NYSE: LLY) has intensified, with Lilly’s Zepbound gaining market share rapidly
All of this means the stock now trades at a forward P/E of just 11.99, a far cry from the premium valuations of 1-2 years ago.
Wall Street analysts appear equally uncertain, with two out of eleven analysts rating the stock a sell, unusual for a major pharmaceutical name. The consensus price target of $56.91 represents only 15.8% upside from current levels, hardly inspiring confidence. The company’s official description as “a premier global healthcare company at the forefront of innovation” rings hollow when earnings are contracting at double-digit rates.
